Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Lawson DH, Jick H, Rothman KJ. Coffee and tea consumption and breast disease. Surgery. 1981 Jan 1;90(5):801-3.